CIRION BIOPHARMA RESEARCH
Acquired by
CERBA HEALTHCARE
CIRION BIOPHARMA RESEARCH acquired by CERBA HEALTHCARE
Target
CIRION BIOPHARMA RESEARCH
Acquirer
CERBA HEALTHCARE
Context
Cerba HealthCare acquired the Canadian CRO Cirion BioPharma Research to integrate it into its global clinical trial business unit, Cerba Research. This move establishes a critical operational hub in North America, allowing the group to offer seamless cross-continental support for drug development programs. The transaction followed Cerba's previous major international acquisitions of Lifebrain (Italy) and Viroclinics-DDL (Netherlands), furthering the global expansion strategy initiated under EQT's majority ownership since 2021.
This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 12.8x since the beginning of 2026, 1.8% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
Cirion is a premier Canadian Contract Research Organization (CRO) specializing in bioanalytical laboratory services for the pharmaceutical and biotechnology industries. The company provides integrated support across the entire drug development lifecycle, from preclinical research to Phase III clinical trials. Key areas of expertise include Pharmacokinetics/Pharmacodynamics (PKPD) assay development, immunogenicity testing, and large molecule analysis. Cirion operates a state-of-the-art facility in Laval that is fully compliant with GLP (Good Laboratory Practice) and North American regulatory standards (FDA/Health Canada), serving a global client base that includes several of the world's top 10 pharmaceutical companies. The team consists of over 80 highly skilled professionals, including PhD holders and medical specialists.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with CIRION BIOPHARMA RESEARCH
mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.